Close



Mar 19, 2024 06:00AM
Mar 19, 2024 06:00AM
Mar 13, 2024 05:58AM
Mar 12, 2024 04:06PM
Mar 12, 2024 04:05PM
Feb 28, 2024 04:05PM
Dec 18, 2023 04:05PM Crinetics Pharmaceuticals (CRNX) Reports Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine
Dec 18, 2023 04:05PM
Nov 7, 2023 04:05PM
Oct 17, 2023 07:00AM
Sep 11, 2023 06:58AM
Sep 10, 2023 10:00AM
Aug 8, 2023 07:00AM
Jul 31, 2023 08:01AM Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
Jun 21, 2023 08:02AM
Jun 21, 2023 07:59AM
Jun 9, 2023 07:30AM
May 4, 2023 04:05PM
Feb 28, 2023 04:05PM
Feb 28, 2023 04:05PM
Jan 9, 2023 08:01AM Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
Jan 9, 2023 08:01AM
Nov 28, 2022 08:09AM
Nov 28, 2022 08:00AM
Nov 14, 2022 08:00AM
Nov 14, 2022 08:00AM
Oct 13, 2022 08:00AM
Oct 13, 2022 08:00AM Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Oct 6, 2022 08:02AM
Oct 6, 2022 08:00AM
Oct 6, 2022 08:00AM
Oct 3, 2022 08:00AM
Oct 3, 2022 08:00AM
Sep 6, 2022 08:00AM
Sep 6, 2022 08:00AM New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly
Aug 12, 2022 08:00AM
Aug 12, 2022 08:00AM
May 25, 2022 07:02AM
May 25, 2022 07:00AM
May 25, 2022 07:00AM
May 12, 2022 04:41PM
May 12, 2022 04:41PM Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Mar 30, 2022 04:02PM
Mar 30, 2022 04:02PM
Mar 30, 2022 04:01PM
Mar 30, 2022 04:01PM
Mar 30, 2022 04:01PM
Mar 1, 2022 08:08AM
Mar 1, 2022 08:00AM Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
Mar 1, 2022 08:00AM

251,895 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All